About this trial
In this prospective, multicenter study of patients with acute spontaneous supratentorial Intracerebral Hemorrhage (ICH), each participant will have a standardized multimodal evaluation of neuroinflammation at 10 (±2) days after onset including translocator protein 18 kDa (TSPO) positron emission tomography (PET) using 18F-DPA-714 radioligand, BBB imaging using Dynamic contrast-enhanced (DCE)-MRI and a panel of pro-inflammatory and anti-inflammatory plasma biomarkers.
Eligibility criteria
Qualifiers
Adults (≥ 18 years old);
presenting with a symptomatic spontaneous supratentorial ICH;
ICH within 48 hours after symptoms onset (or last seen well);
ICH confirmed by brain imaging;
Disqualifiers
Massive ICH volume (≥ 60 ml) at admission;
Severe coma (defined as a Glasgow Coma Scale score < 6) at admission;
Planned neurosurgical hematoma evacuation;
Decision already taken for palliative care with withdrawal of active treatment;
Trial design
Treatments tested in this trial
- TEP with 18F-DPA-714 injection
Treatment groups
Locations
3Sponsors and collaborators
University Hospital, Toulouse
Lead sponsor